delandistrogene moxeparvovec
SRP-9001-303
Phase 3 gene_therapy active
Quick answer
delandistrogene moxeparvovec for Duchenne Muscular Dystrophy is a Phase 3 program (gene_therapy) at Sarepta Therapeutics with 7 ClinicalTrials.gov record(s).
Program details
- Company
- Sarepta Therapeutics
- Indication
- Duchenne Muscular Dystrophy
- Phase
- Phase 3
- Modality
- gene_therapy
- Status
- active